<DOC>
	<DOCNO>NCT00175877</DOCNO>
	<brief_summary>An open end study patient complete double-blind study CDP870-027 [ NCT00152386 ] give Certolizumab Pegol ( CZP ) assess sign symptom Rheumatoid Arthritis ( RA ) .</brief_summary>
	<brief_title>A Study Safety Effectiveness Lyophilized Certolizumab Pegol Treatment Signs Symptoms Rheumatoid Arthritis Prevention Joint Damage Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patients must either fail achieve American College Rheumatology 20 % Response Criteria ( ACR20 ) Weeks 12 14 C87027 [ NCT00152386 ] , must complete entire Week 52 assessment C87027 [ NCT00152386 ] trial . A diagnosis inflammatory Arthritis ( e.g . Psoriatic Arthritis Ankylosing Spondylitis ) A secondary , noninflammatory type Arthritis ( e.g . Osteoarthritis Fibromyalgia ) Investigator 's opinion symptomatic enough interfere evaluation effect CDP870 patient 's primary diagnosis Rheumatoid Arthritis Any concomitant biological therapy Any experimental therapy , within outside clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>CDP870</keyword>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
</DOC>